Microbiology and Immunology · 2002 · 19 citations · 17 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyDna VaccinesRecombinant Vaccine DevelopmentSwine VaccinologyVaccinationVaccine-preventable DiseasesViral VaccinesAntibodiesDeoxyribonucleic Acid (Dna) VaccineDna Vaccines For SwineJapanese Encephalitis VaccinationRecombinant Viral VaccinesVaccine Candidate Antigens
We previously reported that mice immunized with recombinant modified vaccinia virus Ankara (MVA) encoding Japanese encephalitis virus (JEV) prM and E genes were completely protected against JEV challenge (Nam, J.H., Wyatt, L.S., Chae, S.L., Cho, H.W., Park, Y.K., Moss, B. Vaccine 1999,17: 261-268). In this study, we examined the immunogenicity in swine of this recombinant MVA (vJH9) or a DNA vaccine (pcJH-1) expressing the same JEV genes. Although the booster effect in mice with a combination of vJH9, pcJH-1 and inactivated JEV commercial vaccine was not apparent by measuring JEV antibodies, the recombinant MVA vaccine (vJH9) and the DNA vaccine (pcJH-l) efficiently produced neutralizing antibodies in swine and 2 doses of each showed a booster effect in mice and swine. Therefore, both vJH9 and pcJH-1 are good candidates for a second generation JEV vaccine.
17
Tomáš Hanke, Rachel V. Samuel, Tom Blanchard et al. · Journal of Virology · 1999 · 306 citations · Full text
Eiji Konishi, Masaoki Yamaoka, Khin-Sane-Win et al. · Journal of Virology · 1998 · 122 citations · Full text